Long-term outcomes after switching from baricitinib 4 mg to upadacitinib 30 mg in atopic dermatitis: a 144-week retrospective study - PubMed
3 days ago
- #atopic dermatitis treatment
- #JAK inhibitors
- #drug switching
- This 144-week retrospective study investigated long-term outcomes in atopic dermatitis patients who switched from baricitinib 4 mg to upadacitinib 30 mg.
- The research focused on the effectiveness and durability of the treatment switch over an extended period.
- The study highlighted the relevance of Janus kinase inhibitors in managing atopic dermatitis and the potential benefits of transitioning between these specific therapies.